Publications
Detailed Information
Therapeutic Cancer Nanovaccine that Enhances T-cell Responses and Efficacy through Dual Interactions with Dendritic Cells and T Cells : 수지상세포 및 T 세포와 동시에 상호작용하여 T 세포의 반응과 치료효능을 증진시키는 치료용 암 백신
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | 김병수 | - |
dc.contributor.author | 고석형 | - |
dc.date.accessioned | 2023-11-20T04:26:24Z | - |
dc.date.available | 2023-11-20T04:26:24Z | - |
dc.date.issued | 2023 | - |
dc.identifier.other | 000000178398 | - |
dc.identifier.uri | https://hdl.handle.net/10371/196562 | - |
dc.identifier.uri | https://dcollection.snu.ac.kr/common/orgView/000000178398 | ko_KR |
dc.description | 학위논문(박사) -- 서울대학교대학원 : 공과대학 협동과정 바이오엔지니어링전공, 2023. 8. 김병수. | - |
dc.description.abstract | Conventional cancer vaccines, which interact primarily with dendritic cells (DCs) to activate tumor-specific T cells, often fail to achieve sufficient therapeutic efficacy due to suboptimal activation of T cells. To address this problem, a therapeutic cancer nanovaccine that enhances T-cell responses by interacting with both DCs and T cells was developed in this study. This nanovaccine is composed of cancer cell membrane and lipids, forming a liposome-like nanoparticle (CCM-MPLA) that contains monophosphoryl lipid A (MPLA) as an adjuvant. To achieve direct interaction with tumor-specific T cells, anti-CD28 antibodies (aCD28) are conjugated with CCM-MPLA, resulting in CCM-MPLA-aCD28. This nanovaccine can improve the therapeutic efficacy of tumor-specific CD8+ T cells in both presence and absence of DCs. CCM-MPLA-aCD28 induces more activation of tumor-specific CD8+ T cells and demonstrates higher anti-tumor efficacy in mice model comparing with conventional nanovaccines that interact with either DCs (CCM–MPLA) or T cells (CCM–aCD28). Additionally, no significant differences are observed in the level of T cell activation and therapeutic efficacy between CCM–MPLA and CCM–aCD28. This method may contribute to the development of effective personalized therapeutic cancer vaccines containing autologous cancer cell membranes. | - |
dc.description.abstract | 암 특이적 T 세포를 활성화시키기 위해 주로 수지상 세포와 상호작용하는 기존의 암 백신은 T 세포의 최적화되지 않은 활성화로 인해 충분한 치료 효능을 보여주지 못하는 경우가 많다. 본 연구에서는 이러한 문제점을 해결하기 위해 수지상 세포 및 T 세포 모두와 상호작용하는 치료용 암 나노백신을 개발하였다. 이 나노백신은 암 세포막과 리피드들로 구성되며, monophosphoryl lipid A (MPLA)를 면역보조제로 포함하는 리포좀 유사 나노입자 (CCM-MPLA)를 형성한다. 암 특이적 T 세포와의 직접적인 상호작용을 달성하기 위해, CCM-MPLA에 CD28 항체 (aCD28)를 결합하여 CCM-MPLA-aCD28을 생성하였다. 이 나노백신은 수지상 세포의 유무와 무관하게 암 특이적 CD8+ T 세포의 치료 효능을 증가시킬 수 있다. CCM-MPLA-aCD28은 DC (CCM-MPLA) 또는 T 세포 (CCM-aCD28)와 상호작용하는 기존의 나노백신들과 비교해 더 많은 암 특이적 CD8+ T 세포의 활성을 유도하며, 마우스 모델에서 더 높은 항암효과를 보였다. 또한, CCM-MPLA와 CCM-aCD28 사이 T 세포 활성화 정도 및 치료 효능에 유의미한 차이가 발견되지 않았다. 이 방법은 자가 암 세포막을 포함하는 효과적 개인 맞춤 암 백신 개발에 기여할 수 있을 것이다. | - |
dc.description.tableofcontents | Abstract i
Table of Contents iii List of Figures vi Chapter 1. Research backgrounds and purpose 1 1.1. Research backgrounds 1 1.1.1. Cancer immunotherapy 1 1.1.2. Cancer vaccine 3 1.1.3. DC targeting cancer vaccine 4 1.1.4. Cancer vaccine interacting with T cell directly 5 1.2. Purpose of research 6 Chapter 2. Experimental section 10 2.1. Cell culture 10 2.1.1. Cell line culture 10 2.1.2. Primary cell isolation and culture 11 2.2. Preparation of CCM-MPLA-aCD28 12 2.2.1. Isolation of cancer cell membrane 12 2.2.2. Characterization of cancer cell membrane 13 2.2.3. Preparation of CCM-MPLA 13 2.2.4. Preparation of CCM-MPLA-aCD28 14 2.2.5. Characterization of CCM-MPLA-aCD28 15 2.2.6. Analysis of CCM-MPLA-aCD28 composition 16 2.3. In vitro assays 17 2.3.1. In vitro interaction of CCM-MPLA-aCD28s with DCs and T cells 17 2.3.2. In vitro viability test 17 2.3.3. In vitro DC activation 17 2.3.4. In vitro T cell proliferation and activation 18 2.4. In vivo antitumor efficacy of CCM-MPLA-aCD28 20 2.4.1. In vivo DC activation 20 2.4.2. Biodistribution of CCM-MPLA-aCD28 20 2.4.3. In vivo interaction of CCM-MPLA-aCD28 with DCs and T cells 21 2.4.4. In vivo toxicity test 21 2.4.5. In vivo tumor growth 22 2.4.6. Tumor-infiltrating lymphocytes (TIL) analysis 23 2.4.7. Animal study approval 23 2.4.8. Statistical analyses 24 Chapter 3. CCM-MPLA-aCD28 for cancer treatment 25 3.1. Characterization of CCM-MPLA-aCD28 25 3.2. Composition of CCM-MPLA-aCD28 28 3.3. Interaction of CCM-MPLA-aCD28 with DCs 32 3.4. Interaction of CCM-MPLA-aCD28 with T cells 36 3.5. Interaction of CCM-MPLA-aCD28 with DCs and T cells 40 3.6. Biodostribution of CCM-MPLA-aCD28 42 3.7. In vivo toxicity of CCM-MPLA-aCD28 44 3.8. The antitumor efficacy of CCM-MPLA-aCD28 46 3.9. TIL anlysis 49 Chapter 4. Conclusion 51 Reference 53 Abstract in Korean 58 | - |
dc.format.extent | vi, 59 | - |
dc.language.iso | eng | - |
dc.publisher | 서울대학교 대학원 | - |
dc.subject | cancer immunotherapy | - |
dc.subject | cancer vaccine | - |
dc.subject | T cell | - |
dc.subject | dendritic cell | - |
dc.subject | cancer cell membrane | - |
dc.subject.ddc | 660.6 | - |
dc.title | Therapeutic Cancer Nanovaccine that Enhances T-cell Responses and Efficacy through Dual Interactions with Dendritic Cells and T Cells | - |
dc.title.alternative | 수지상세포 및 T 세포와 동시에 상호작용하여 T 세포의 반응과 치료효능을 증진시키는 치료용 암 백신 | - |
dc.type | Thesis | - |
dc.type | Dissertation | - |
dc.contributor.AlternativeAuthor | Go, Seokhyeong | - |
dc.contributor.department | 공과대학 협동과정 바이오엔지니어링전공 | - |
dc.description.degree | 박사 | - |
dc.date.awarded | 2023-08 | - |
dc.identifier.uci | I804:11032-000000178398 | - |
dc.identifier.holdings | 000000000050▲000000000058▲000000178398▲ | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.